New combo attack on leukemia shows promise in early trial
NCT ID NCT05306301
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding the targeted drug ponatinib to standard chemotherapy can improve outcomes for adults with a specific, high-risk type of acute lymphoblastic leukemia called BCR/ABL1-like ALL. The study enrolls 32 patients aged 18-65 who have not yet been treated. The main goal is to see how many achieve a deep remission (MRD negativity) after three cycles of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ponatinib (a targeted drug that blocks cancer growth signals)
What this could lead to
If successful, this could offer a more effective first-line treatment for a hard-to-treat form of acute lymphoblastic leukemia, potentially improving remission rates.
What could go wrong
This is a small Phase 2 study (32 people) with no control group, so results may not be definitive. Ponatinib can cause serious side effects like blood clots, pancreatitis, and liver problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, ACUTE LYMPHOBLASTIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dipartimento di Medicina Traslazionale e di Precisione - Ematologia
Roma, Italy
-
Ematologi Presidio Ospedaliero Guglielmo da Saliceto
Piacenza, Italy
-
Ematologia AO Ospedali Riuniti Villa Sofia Cervello
Palermo, Italy
-
Ematologia AOU Careggi
Florence, Italy
-
Ematologia AOU Federico II
Naples, Italy
-
Ematologia AOU Maggiore della Carità
Novara, Italy
-
Ematologia AOU Policlinico Tor Vergata
Roma, Italy
-
Ematologia AOU Policlinico Vittorio Emanuele-Ferrarotto
Catania, Italy
-
Ematologia AOU S.ORSOLA-MALPIGHI
Bologna, Italy
-
Ematologia AOU Senese
Siena, Italy
-
Ematologia ASST Papa Giovanni XXIII
Bergamo, Italy
-
Ematologia ASST Spedali Civili
Brescia, Italy
-
Ematologia Fondazione Policlinico San Matteo
Pavia, Italy
-
Ematologia Ospedale Maggiore Policlinico
Milan, Italy
-
Ematologia Ospedale Mauriziano
Torino, Italy
-
Ematologia Ospedale S.Giovanni Battista Molinette
Torino, Italy
-
Ematologia Ospedale V.Fazzi
Lecce, Italy
-
Ematologia Ospedale dell'Angelo
Mestre, Italy
-
Ematologia Policlinico A.Gemelli
Roma, Italy
-
Ematologia Policlinico G.B. Rossi
Verona, Italy
-
Ematologia Presidio Ospedaliero Infermi
Rimini, Italy
-
Ematologia Presidio Ospedaliero Spirito Santo
Pescara, Italy
-
Ematologia Presidio Ospedaliero Tortora
Pagani, SA, Italy
-
Ematologia con Unità di Trapianto
Avellino, AV, 83100, Italy